RFS Pharma, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects

Phase 2

Withdrawn

Conditions: Human Immunodeficiency Virus Infection

Interventions: Drug: amdoxovir 500 mg bid
Drug: amdoxovir 300 mg bid

First Posted Date: 2012-11-30

Last Posted Date: 2013-03-29

Lead Sponsor: RFS Pharma, LLC

Registration Number: NCT01738555

A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.

Phase 2

Terminated

Conditions: Human Immunodeficiency Virus Infection

Interventions: Drug: amdoxovir 300 mg bid
Drug: amdoxovir 500 mg bid
Drug: tenofovir DF 300 mg qd

First Posted Date: 2012-11-29

Last Posted Date: 2014-11-05

Lead Sponsor: RFS Pharma, LLC

Target Recruit Count: 2

Registration Number: NCT01737359

Locations: 🇦🇷
Research Site, Buenos Aires, Argentina

Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2007-02-06

Last Posted Date: 2007-05-11

Lead Sponsor: RFS Pharma, LLC

Target Recruit Count: 24

Registration Number: NCT00432016

Locations: 🇦🇷
Hospital Privado Modelo, Buenos Aires, Argentina

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy